Press Releases

GI Dynamics Announces EndoBarrier Data to be Presented at Digestive Disease Week

BOSTON and SYDNEY — 4 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced that new EndoBarrier data will be presented at Digestive Disease Week®...

read more

GI Dynamics Selects Allenby Capital to Explore AIM Listing Option

BOSTON and SYDNEY — 3 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces Allenby Capital Limited’s engagement to explore options for seeking...

read more

GI Dynamics to Release 2016 Annual Report and Host Webcast for Year Ending 31 December 2016

BOSTON and SYDNEY – 23 March 2017 – GI Dynamics, Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe and the Middle East for patients with type 2 diabetes and obesity, announced that it will release its 2016 Annual Report on Form 10K on or before 31 March EDT |...

read more

GI Dynamics Announces Scientific Advisory Board Members to Further Scientific Understanding of EndoBarrier

BOSTON and SYDNEY — 13 March 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced additional members of the GI Dynamics Scientific Advisory Board...

read more

GI Dynamics Announces New Scientific Advisory Board and Board’s First Two Members

BOSTON and SYDNEY — 7 March 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced the creation of the GI Dynamics Scientific Advisory Board (SAB).  The...

read more

EndoBarrier® Study in Morbidly Obese Adolescents Completes Enrollment

First study of EndoBarrier in adolescents completed at University Children’s Hospital (UCH) in Ljubljana, Slovenia Preliminary data show BMI reduced by 10 percent Acceptable safety profile and improvement in metabolic parameters BOSTON and SYDNEY — 16 February 2017 — GI Dynamics, Inc. (ASX:GID), a...

read more

EndoBarrier® Receives German NUB Reimbursement Status 1 for Type 2 Diabetes and Obesity Therapy

FOR IMMEDIATE RELEASE BOSTON and SYDNEY — 1 February 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier in Europe for patients with type 2 diabetes and obesity, announces that InEk, the German Institute for the Hospital Remuneration System, has...

read more

GI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review

BOSTON and SYDNEY — 11 January 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today released a 2017 business outlook and recap of 2016 accomplishments. 2017 marks the first full calendar...

read more

GI Dynamics, Inc. Appoints Oern R. Stuge, MD, MBA, Amid Change to Company’s Board of Directors

BOSTON and SYDNEY — 5 January 2017 — GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, today announced the appointment of veteran medical device executive Oern Stuge, M.D., MBA,...

read more

GI Dynamics, Inc. Announces Completion of A $1.5million Private Placement and Launch of Security Purchase Plan

GI Dynamics®, (ASX:GID) a medical technology company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity is pleased to announce that it has received commitments for a private placement of 69,865,000 fully paid CHESS Depositary...

read more
Page 2 of 1812345...10...Last »